Search Results - "Howgate E"

Author Index.

Source: Drug Metabolism Reviews. 2005 Supplement 1, Vol. 37, p83-89. 7p.

Evaluation of in vitro drug-drug interactions of ivermectin and antimalarial compounds.

Authors: Tipthara, Phornpimon Kullasakboonsri, Rattawan Kobylinski, Kevin C. et al.

Source: Malaria Journal. 9/24/2025, Vol. 24 Issue 1, p1-7. 7p.

Supplementing clinical lactation studies with PBPK modeling to inform drug therapy in lactating mothers: Prediction of primaquine exposure as a case example.

Authors: Pan, Xian Abduljalil, Khaled Almond, Lisa M. et al.

Source: CPT: Pharmacometrics & Systems Pharmacology. Mar2024, Vol. 13 Issue 3, p386-395. 10p.

MDMA pharmacokinetics: A population and physiologically based pharmacokinetics model‐informed analysis.

Authors: Huestis, Marilyn A. Smith, William B. Leonowens, Cathrine et al.

Source: CPT: Pharmacometrics & Systems Pharmacology. Feb2025, Vol. 14 Issue 2, p376-388. 13p.

Systematic Analysis of Threats to Sea Turtles in Mexico: Trends, Knowledge Gaps, and Implications for Conservation.

Authors: Ramírez-Villanueva, Ruth I. Gumeta-Gómez, Fernando Hinojosa-Arango, Gustavo

Source: Oceans (2673-1924). Dec2025, Vol. 6 Issue 4, p71. 22p.

Development and application of a PBPK modeling strategy to support antimalarial drug development.

Authors: Abla, Nada Howgate, Eleanor Rowland‐Yeo, Karen et al.

Source: CPT: Pharmacometrics & Systems Pharmacology. Sep2023, Vol. 12 Issue 9, p1335-1346. 12p.

Improving In Vitro–In Vivo Correlation (IVIVC) for Lipid-Based Formulations: Overcoming Challenges and Exploring Opportunities.

Authors: Bourderi-Cambon, Arnaud Fadhlaoui, Khaled Garrait, Ghislain et al.

Source: Pharmaceutics. Oct2025, Vol. 17 Issue 10, p1310. 26p.

Physiologically based pharmacokinetic modelling to predict artemether and lumefantrine exposure in neonates weighing less than 5 kg treated with artemether–lumefantrine to supplement the clinical data from the CALINA study.

Authors: Gu, Helen Abla, Nada Venishetty, Vinay Kumar et al.

Source: Tropical Medicine & Health. 8/25/2025, Vol. 53 Issue 1, p1-17. 17p.

PBPK‐led assessment of antimalarial drugs as candidates for Covid‐19: Simulating concentrations at the site of action to inform repurposing strategies.

Authors: Abla, Nada Almond, Lisa M. Bonner, Jennifer J. et al.

Source: CTS: Clinical & Translational Science. Jul2024, Vol. 17 Issue 7, p1-11. 11p.

Randomized, placebo‐controlled, double‐blind phase I trial of co‐administered pyronaridine and piperaquine in healthy adults of sub‐Saharan origin.

Authors: Kuemmerle, Andrea Gossen, Denis Janin, Annick et al.

Source: CTS: Clinical & Translational Science. Apr2024, Vol. 17 Issue 4, p1-14. 14p.

Advancements in Virtual Bioequivalence: A Systematic Review of Computational Methods and Regulatory Perspectives in the Pharmaceutical Industry.

Authors: Alotaiq, Nasser Dermawan, Doni

Source: Pharmaceutics. Nov2024, Vol. 16 Issue 11, p1414. 18p.

A tutorial on physiologically based pharmacokinetic approaches in lactation research.

Authors: Pansari, Amita Pan, Xian Almond, Lisa M. et al.

Source: CPT: Pharmacometrics & Systems Pharmacology. Nov2024, Vol. 13 Issue 11, p1841-1855. 15p.

A Population Pharmacokinetic Assessment of the Effect of Food on Selumetinib in Patients with Neurofibromatosis Type 1‐Related Plexiform Neurofibromas and Healthy Volunteers.

Authors: Zuo, Peiying Arefayene, Million Pan, Wei‐Jian et al.

Source: Clinical Pharmacology in Drug Development. Jul2024, Vol. 13 Issue 7, p770-781. 12p.

Population Pharmacokinetic Analysis of Selumetinib and Its N-desmethyl Metabolite in Japanese and Non-Japanese Pediatric Patients with Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas.

Authors: Shinbo, Takumi Higashimori, Mitsuo González-García, Ignacio et al.

Source: Journal of Clinical Pharmacy & Therapeutics. 5/14/2024, Vol. 2024, p1-11. 11p.

Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences.

Authors: Inoue, S. Howgate, E. M. Rowland-Yeo, K. et al.

Source: Xenobiotica. Jun2006, Vol. 36 Issue 6, p499-513. 15p. 4 Charts, 5 Graphs.

Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability.

Authors: Howgate, E. M. Rowland Yeo, K. Proctor, N. J. et al.

Source: Xenobiotica. Jun2006, Vol. 36 Issue 6, p473-497. 25p. 4 Charts, 7 Graphs.

Lifespan estimation in marine turtles using genomic promoter CpG density.

Authors: Mayne, Benjamin Tucker, Anton D. Berry, Oliver et al.

Source: PLoS ONE. 7/31/2020, Vol. 15 Issue 7, p1-8. 8p.

Inferring Therapeutic Targets in Candida albicans and Possible Inhibition through Natural Products: A Binding and Physiological Based Pharmacokinetics Snapshot.

Authors: Basharat, Zarrin Khan, Kanwal Jalal, Khurshid et al.

Source: Life (2075-1729). Nov2022, Vol. 12 Issue 11, p1743. 15p.

Population pharmacokinetic model with time‐varying clearance for lorlatinib using pooled data from patients with non‐small cell lung cancer and healthy participants.

Authors: Chen, Joseph Houk, Brett Pithavala, Yazdi K. et al.

Source: CPT: Pharmacometrics & Systems Pharmacology. Feb2021, Vol. 10 Issue 2, p148-160. 13p.

Semi-mechanistic modelling platform to assess cardiac contractility and haemodynamics in preclinical cardiovascular safety profiling of new molecular entities.

Authors: Venkatasubramanian, Raja Collins, Teresa A. Lesko, Lawrence J. et al.

Source: British Journal of Pharmacology. Aug2020, Vol. 177 Issue 15, p3568-3590. 23p. 1 Diagram, 3 Charts, 3 Graphs.